Marshall Wace, LLP Viking Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 73,700 shares of VKTX stock, worth $4.54 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
73,700
Previous 371,686
80.17%
Holding current value
$4.54 Million
Previous $30.5 Million
87.18%
% of portfolio
0.01%
Previous 0.05%
Shares
8 transactions
Others Institutions Holding VKTX
# of Institutions
442Shares Held
63.3MCall Options Held
6.23MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$622 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$371 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$316 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$139 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$115 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.73B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...